For this narrative review, we performed research on pubmed.gov, clinicaltrials.gov and google.scholar using the keywords ‘endometrial cancer’, ‘endometrial cancer stem cell’, ‘endometrial neoplasm’, ‘endometrioid carcinoma’, ‘uterine cancer’ and ‘uterine cancer stem cell’ together with specific keywords like ‘tumorigenicity’, ‘signaling’, ‘stemness’, ‘pluripotency’, ‘immunotherapy’ and ‘metabolism’ as well as ‘wnt’, ‘PI3K’, ‘Akt’, ‘notch’, ‘CD133/C44‘, ‘nfkb’, ‘nuclear factor kappa b’, ‘RelA’, ‘myc’, ‘mitochondria’, ‘PD-L1’ and ‘pembrolizumab’. This evidence concerns the gene PROM1 and endometrioid adenocarcinoma.